Boston Oncology

Class-Leading Biogenerics

Boston Oncology maintains a diverse and extensive portfolio of best-in-class generic and biosimilar therapeutics—USFDA / EMA registered and licensed from world-renowned innovator companies—supporting the entire patient journey.

Class-leading generics and biosimilars, supporting the entire patient journey
Boston Oncology Arabia Facility

We are very proud of our reputation for anticipating demand, and growing our portfolio with precision. Our products include the most widely used formulations in critical care, oncology, and pain relief—offering a comprehensive solution to healthcare providers and hospitals.

Leveraging our Global footprint and extensive International experience, Boston Oncology is able to secure licensing agreements for the best formulations in the US and European markets. We deliver products of unparalleled quality by creating modular and highly flexible local manufacturing facilities, sourcing API from the same batches manufactured for the US and European markets; and even pursuing regional approvals using the same files submitted for the original USFDA / EMA registration.

Boston Oncology is aggressively pursuing a research and development program to offer next generation treatments through critical care medicines, specialty generics, oncology products, orphan drugs, and narcotics.

USFDA / EMA Registered and Licensed Therapeutics

Product Portfolio

Oncology

Birato  |  250 mg, 500 mg  |  Tablet

Bortezomib BOS  |  3.5 mg  |  Powder for solution for injection

Emcap  |  500 mg  |  Tablet

Allbloc  |  1 mg/mL  |  Concentrate for solution for infusion

Tykodas  |  50 mg, 70 mg, 100 mg  |  Film-coated tablet

Docadex  |  20 mg, 80 mg  |  Concentrate for solution for infusion

Gemcitabine BOS  |  1000 mg  |  Concentrate for solution for infusion

Citarox  |  1000 mg, 200 mg  | Powder for solution for injection

Tecana  |  20 mg/mL  |  Powder for solution for injection

Lenvatinib TBM  |  10 mg  |  Capsule

Xorola  |  2.5 mg  |  Film-coated tablet

Batipan  |  50 mg, 100 mg  |  Powder for solution for injection

Pemitax  |  500 mg  |  Powder for solution for injection

Sorafenat  |  200 mg  |  Film-coated tablet

Apeto  |  15 mg, 100 mg   |  Powder for solution for injection

Sermitor  |  60 mg  |  Tablet

Critical Care

Demexa  |  100 mcg  |  Solution for injection

Milrinone BOS  |  1 mg/mL  |  Solution for injection

Ketorolac BOS   |  30 mg/mL  |  Solution for injection

Tranexamic Acid BOS  |  100 mg  |  Powder for solution for injection

Rocuronium BOS  |  10 mg/mL  |  Solution for injection

Speciality Generics

Ferasiro  |  90 mg, 180 mg, 360 mg  |  Film-coated tablet

Envona  |  150 mg  |  Powder for solution for infusion 

Levetiracetam TBM  |  100 mg  |  Injection

Teriflunomide BOS  |  14 mg  |  Film-coated tablet

Hemabo  |  24 mg/mL  |  Solution for injection 

Fenido  |  267 mg, 801 mg  |  Film-coated tablet

Acidoxax  |  4 mg  |  Concentrate for solution for infusion

Anti-infective

Anidulafungin BOS  |  100 mg  |  Powder for concentrate for solution 

Azithromycin TBM  |  500 mg  |  Powder for solution for injection

Copsfin  |  50 mg, 70 mg  | Powder for concentrate for solution

Daptomycin BOS  |  350 mg  |  Powder for solution for injection or infusion

Foscarnet BOS  |  24 mg/mL  | Solution for infusion

Oselow  |  75 mg  | Capsule

Tigecycline BOS  |  50 mg/vial  |  Powder for infusion

Voriole  |  200 mg  |  Powder for solution for infusion

Biosimilar

Enoxaparin BOS  |  20 mg, 40 mg, 60 mg, 80 mg  |  Solution for injection